Department of Anesthesia & Perioperative Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
London Health Sciences Centre, London, ON, Canada.
Can J Anaesth. 2023 Sep;70(9):1461-1473. doi: 10.1007/s12630-023-02510-6. Epub 2023 Jul 8.
The scientific rigour of the conduct and reporting of anesthesiology network meta-analyses (NMAs) is unknown. This systematic review and meta-epidemiological study assessed the methodological and reporting quality of NMAs in anesthesiology.
We searched four databases, including MEDLINE, PubMed, Embase, and the Cochrane Systematic Reviews Database, for anesthesiology NMAs published from inception to October 2020. We assessed the compliance of NMAs against A Measurement Tool to Assess Systematic Reviews (AMSTAR-2), Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement for Network Meta-Analyses (PRISMA-NMA), and PRISMA checklists. We measured the compliance across various items in AMSTAR-2 and PRISMA checklists and provided recommendations to improve quality.
Using the AMSTAR-2 rating method, 84% (52/62) of NMAs were rated "critically low." Quantitatively, the median [interquartile range] AMSTAR-2 score was 55 [44-69]%, while the PRISMA score was 70 [61-81]%. Methodological and reporting scores showed a strong correlation (R = 0.78). Anesthesiology NMAs had a higher AMSTAR-2 score and PRISMA score if they were published in higher impact factor journals (P = 0.006 and P = 0.01, respectively) or followed PRISMA-NMA reporting guidelines (P = 0.001 and P = 0.002, respectively). Network meta-analyses from China had lower scores (P < 0.001 and P < 0.001, respectively). Neither score improved over time (P = 0.69 and P = 0.67, respectively).
The current study highlights numerous methodological and reporting deficiencies in anesthesiology NMAs. Although the AMSTAR tool has been used to assess the methodological quality of NMAs, dedicated tools for conducting and assessing the methodological quality of NMAs are urgently required.
PROSPERO (CRD42021227997); first submitted 23 January 2021.
麻醉学网络荟萃分析(NMAs)的实施和报告的科学严谨性尚不清楚。本系统评价和荟萃流行病学研究评估了麻醉学 NMAs 的方法学和报告质量。
我们在 MEDLINE、PubMed、Embase 和 Cochrane 系统评价数据库中检索了从成立到 2020 年 10 月发表的麻醉学 NMAs。我们根据 A 测量工具评估 NMAs 对系统评价的一致性(AMSTAR-2)、系统评价和荟萃分析的首选报告项目声明(PRISMA-NMA)和 PRISMA 清单。我们衡量了 AMSTAR-2 和 PRISMA 清单中各项的一致性,并提出了改进质量的建议。
使用 AMSTAR-2 评分方法,84%(52/62)的 NMAs 被评为“严重低质量”。定量地,中位数[四分位间距]AMSTAR-2 评分为 55[44-69]%,而 PRISMA 评分为 70[61-81]%。方法学和报告评分显示出很强的相关性(R = 0.78)。如果 NMAs 发表在影响因子较高的期刊上(P = 0.006 和 P = 0.01)或遵循 PRISMA-NMA 报告指南(P = 0.001 和 P = 0.002),则麻醉学 NMAs 的 AMSTAR-2 评分和 PRISMA 评分更高。来自中国的网络荟萃分析得分较低(P < 0.001 和 P < 0.001)。两个评分都没有随着时间的推移而提高(P = 0.69 和 P = 0.67)。
本研究突出了麻醉学 NMAs 中存在的许多方法学和报告缺陷。虽然 AMSTAR 工具已被用于评估 NMAs 的方法学质量,但迫切需要专门的工具来进行和评估 NMAs 的方法学质量。
PROSPERO(CRD42021227997);首次提交于 2021 年 1 月 23 日。